Brain+ A/S Logo

Brain+ A/S

BRAINP.CO

(1.0)
Stock Price

0,09 DKK

-53.11% ROA

-160.52% ROE

-0.37x PER

Market Cap.

16.568.341,00 DKK

0% DER

0% Yield

-1138.63% NPM

Brain+ A/S Stock Analysis

Brain+ A/S Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Brain+ A/S Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

The stock's ROE indicates a negative return (-52.34%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-113.51%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Brain+ A/S Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Brain+ A/S Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Brain+ A/S Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Brain+ A/S Revenue
Year Revenue Growth
2015 2.699.990
2016 1.973.596 -36.81%
2017 4.342.938 54.56%
2018 6.021.457 27.88%
2019 5.272.000 -14.22%
2020 6.009.000 12.26%
2021 3.992.214 -50.52%
2022 3.232.617 -23.5%
2023 2.352.491 -37.41%
2024 4.130.692 43.05%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Brain+ A/S Research and Development Expenses
Year Research and Development Expenses Growth
2015 510.435
2016 408.348 -25%
2017 408.348 0%
2018 408.348 0%
2019 1.224.630 66.66%
2020 1.594.729 23.21%
2021 1.594.728 -0%
2022 1.594.729 0%
2023 3.921.108 59.33%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Brain+ A/S General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 -9.653.213 100%
2022 -12.689.278 23.93%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Brain+ A/S EBITDA
Year EBITDA Growth
2015 -634.300
2016 -494.830 -28.19%
2017 -608.500 18.68%
2018 -495.420 -22.83%
2019 -1.645.000 69.88%
2020 192.348 955.22%
2021 -5.557.122 103.46%
2022 -9.439.440 41.13%
2023 -12.608.290 25.13%
2024 -18.511.520 31.89%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Brain+ A/S Gross Profit
Year Gross Profit Growth
2015 2.699.990
2016 1.974 -136677.61%
2017 4.343 54.55%
2018 6.085 28.63%
2019 5.272.000 99.88%
2020 6.009.000 12.26%
2021 3.992.214 -50.52%
2022 3.232.617 -23.5%
2023 2.352.491 -37.41%
2024 4.130.692 43.05%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Brain+ A/S Net Profit
Year Net Profit Growth
2015 -447.814
2016 -389.776 -14.89%
2017 -582.787 33.12%
2018 -462.187 -26.09%
2019 -1.513.000 69.45%
2020 -1.279.000 -18.3%
2021 -7.079.752 81.93%
2022 -9.679.595 26.86%
2023 -19.124.815 49.39%
2024 -28.231.008 32.26%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Brain+ A/S Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 -608 100%
2018 -482 -26.14%
2019 0 0%
2020 -9 100%
2021 -1 0%
2022 -1 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Brain+ A/S Free Cashflow
Year Free Cashflow Growth
2016 0
2017 0 0%
2018 0 0%
2019 16.312 100%
2020 290.725 94.39%
2021 -15.740.567 101.85%
2022 -9.049.112 -73.95%
2023 -17.220.499 47.45%
2024 -7.449.950 -131.15%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Brain+ A/S Operating Cashflow
Year Operating Cashflow Growth
2016 0
2017 0 0%
2018 0 0%
2019 16.312 100%
2020 7.290.898 99.78%
2021 -8.382.370 186.98%
2022 -4.025.370 -108.24%
2023 -13.707.331 70.63%
2024 -5.396.996 -153.98%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Brain+ A/S Capital Expenditure
Year Capital Expenditure Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 7.000.173 100%
2021 7.358.197 4.87%
2022 5.023.742 -46.47%
2023 3.513.168 -43%
2024 2.052.954 -71.13%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Brain+ A/S Equity
Year Equity Growth
2015 6.470.079
2016 6.080.302 -6.41%
2017 6.697.353 9.21%
2018 6.235.166 -7.41%
2019 3.197.000 -95.03%
2020 1.918.000 -66.68%
2021 20.604.018 90.69%
2022 16.382.902 -25.77%
2023 12.384.756 -32.28%
2024 12.669.083 2.24%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Brain+ A/S Assets
Year Assets Growth
2015 9.117.868
2016 11.146.263 18.2%
2017 16.247.108 31.4%
2018 22.768.921 28.64%
2019 23.810.000 4.37%
2020 29.889.000 20.34%
2021 46.883.117 36.25%
2022 45.372.160 -3.33%
2023 35.969.780 -26.14%
2024 37.859.138 4.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Brain+ A/S Liabilities
Year Liabilities Growth
2015 2.647.789
2016 5.065.961 47.73%
2017 9.549.756 46.95%
2018 16.533.755 42.24%
2019 20.613.000 19.79%
2020 27.971.000 26.31%
2021 26.279.099 -6.44%
2022 28.989.258 9.35%
2023 23.585.024 -22.91%
2024 25.190.055 6.37%

Brain+ A/S Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.02
Net Income per Share
-0.25
Price to Earning Ratio
-0.37x
Price To Sales Ratio
9.38x
POCF Ratio
-5.63
PFCF Ratio
-4.9
Price to Book Ratio
0.59
EV to Sales
6.73
EV Over EBITDA
-1.36
EV to Operating CashFlow
-8.95
EV to FreeCashFlow
-3.52
Earnings Yield
-2.69
FreeCashFlow Yield
-0.2
Market Cap
0,02 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.94
Graham NetNet
-0.24

Income Statement Metrics

Net Income per Share
-0.25
Income Quality
0.1
ROE
-1.61
Return On Assets
-0.53
Return On Capital Employed
-0.53
Net Income per EBT
0.97
EBT Per Ebit
1.18
Ebit per Revenue
-9.96
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
1
Operating Profit Margin
-9.96
Pretax Profit Margin
-11.71
Net Profit Margin
-11.39

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
-1.55
Capex to Revenue
1.16
Capex to Depreciation
0.5
Return on Invested Capital
-1.35
Return on Tangible Assets
-0.53
Days Sales Outstanding
299.72
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
1.22
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0.03

Balance Sheet

Cash per Share
0,06
Book Value per Share
0,16
Tangible Book Value per Share
0.16
Shareholders Equity per Share
0.16
Interest Debt per Share
0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.53
Current Ratio
1.4
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
1785666
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Brain+ A/S Dividends
Year Dividends Growth

Brain+ A/S Profile

About Brain+ A/S

Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer's. In addition, it develops an interface for clinicians to track and trace the patient's treatment progress. The company was incorporated in 2012 and is based in Copenhagen, Denmark. Brain+ A/S was formerly a subsidiary of Brain+ Holding ApS.

CEO
Mr. Kim Baden-Kristensen
Employee
20
Address
KOebmagergade 53
Copenhagen, 1150

Brain+ A/S Executives & BODs

Brain+ A/S Executives & BODs
# Name Age
1 Mr. Rasmus Højengaard
Founder and CCO
70
2 Mr. Bjarke Langbol Panduro
Marketing & Product Mang.
70
3 Ms. Paula Petcu
Chief Technology Officer
70
4 Ms. Hanne Leth Hillman M.Sc.
Interim Chief Financial Officer
70
5 Mr. Kim Baden-Kristensen
Founder, Chief Executive Officer & MD
70
6 Mr. Simon Nielsen
Chief Science & Innovation Officer
70
7 Mr. Bertil Stengaard Jessen
Chief Financial Officer (Leave of Absence)
70

Brain+ A/S Competitors